Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation - Wikidata - wikimedia - TriplyDB

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

http://www.wikidata.org/entity/Q36734132

about

The promises of quantitative systems pharmacology modelling for drug development Improving the tools of clinical pharmacology: Goals for 2017 and beyond.A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.Optimizing drug development in oncology by clinical trial simulation: Why and how?Commentary on the MID3 Good Practices Paper.Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap.Quantitative Systems Pharmacology: A Case for Disease Models.Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.Model Description Language (MDL): A Standard for Modeling and Simulation.An automated sampling importance resampling procedure for estimating parameter uncertainty.How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?Scientific white paper on concentration-QTc modeling.Assessing similarity among individual tumor size lesion dynamics: The CICIL methodology.The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine.Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.Development and performance of npde for the evaluation of time-to-event models.Integrating dose estimation into a decision-making framework for model-based drug development.Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use.Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference.Model reduction in mathematical pharmacology : Integration, reduction and linking of PBPK and systems biology models.Proposed best practice for projects that involve modelling and simulation.Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.Harvesting the promise of AOPs: An assessment and recommendations Perspective on the State of Pharmacometrics and Systems Pharmacology Integration The Standard Output: A Tool-Agnostic Modeling Storage Format

P2860

Q28077650-23066B08-6057-4CCB-815A-1CA2483E18BF Q36160617-63391EB7-26AC-4FC6-AE4D-336850A5CC10 Q37733479-D54431E6-9214-420B-AF11-36B895FE7A68 Q38675644-EE60628B-C94D-473F-828B-868CEA40F28C Q38707591-3EF8BFFB-3A45-43DF-9924-8BB521B209C8 Q38786202-73993BCF-360A-4063-99A6-1B8D4F151885 Q38888255-125FACDF-A7E6-446C-86C1-AFE254B4FF5C Q39300563-552A2CDE-9104-48BE-983A-6A9B1057D814 Q40889594-F56EFD7A-9D78-4263-A1EE-67EFDA70AA4A Q42337873-75AE55D6-9A21-451F-ACB9-113EB391F1EB Q42359116-BC736A91-8148-46B0-9FFF-1FC6AC3D7165 Q42621642-A7221186-C134-405F-B52A-1DABC56A0AD7 Q46078169-BBC62452-C37D-4369-92B3-B4F246EB7500 Q47255442-048AB3A5-5D8B-479C-8307-291E0788F0C3 Q47361141-FAAD9FE1-5D42-48A9-8EF5-D6B1AC96A577 Q47553750-DFEAE3E4-CFDA-43F6-B2F8-4047E674AD7C Q47693272-305AB0F5-E143-479E-82F6-25FD1D876059 Q47724152-A85D4D42-4C68-4E82-9441-6B31932F92CA Q48170803-E181D776-9749-4A3C-9F89-336087562F0C Q48263903-09C16879-9C73-4679-9FB3-38454ED5DFD6 Q50057323-3F3BEE69-EC3F-4F16-A4A1-2FBA96F7C7B5 Q50673342-B42E2249-83B5-4346-8548-E49069F9BA93 Q51734162-FBF9A000-71FD-4DF8-9FA8-442A7FEDE415 Q52841716-DAFC1E65-DBE0-41B7-9907-C2EA9804F897 Q55470248-6FD91B2B-8C00-4462-8358-F5A9274D3C8C Q57178963-826A1C10-8C1F-42CF-A467-C4BD29F573DB Q58724707-5A514179-A416-44E8-9811-38406751EFD6 Q58787590-964197EB-F2F6-4004-9C2B-70DCEBA62D54

P2860

Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation

http://www.wikidata.org/entity/Q36734132

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Good Practices in Model-Inform ...... Application, and Documentation

@ast

Good Practices in Model-Inform ...... Application, and Documentation

@en

type

label

Good Practices in Model-Inform ...... Application, and Documentation

@ast

Good Practices in Model-Inform ...... Application, and Documentation

@en

prefLabel

Good Practices in Model-Inform ...... Application, and Documentation

@ast

Good Practices in Model-Inform ...... Application, and Documentation

@en

P1433

Q36734132-A6203A43-B83D-402D-BDEA-958A83C8E344

P1476

Q36734132-F6FBB921-A52D-43C5-88C9-466376A735D2

P2093

Q36734132-01CB32CC-1303-401A-B7E2-63C96E16CDA4

Q36734132-17D6F0E2-AC1B-41BC-8180-D41C1CE572BD

Q36734132-266F2ECC-3820-4278-90FE-E6614D3A50ED

Q36734132-5009EE29-FDBC-43A4-8775-4982354C2793

Q36734132-57B2FFB9-4785-4BA8-9DB3-4569098D51FD

Q36734132-6A6D6D5A-F67E-49A5-A633-B942964023B0

Q36734132-777DEDAA-D05F-441E-AC60-016C3B7E247C

Q36734132-79CD728F-85FD-4DF0-9B43-B6422E239990

Q36734132-8ACDA913-8455-43C6-B291-F45E5B4041F1

Q36734132-8D813426-73A5-48F3-AAC6-E7B908AF6849

P2860

Q36734132-0088FAA6-1078-4F97-AE70-23DCB92D02E5

Q36734132-0182659A-0AF5-46B6-B810-67A9CED19F98

Q36734132-077863A6-31F3-46B7-A741-286E6B165D27

Q36734132-07E9345C-15BB-48F3-8E96-6756B6CA9683

Q36734132-09A8C1E5-C119-4457-884B-882B3F709F29

Q36734132-0D96B44E-7389-4B63-A8A5-1C08D9432900

Q36734132-10B570FE-1A3D-4802-8CB2-F83B51CA97CF

Q36734132-10DB2C52-1729-4C90-B9DC-A00B3764D47F

Q36734132-13336929-3B2A-4613-8FC5-78193B54940B

Q36734132-1493298F-F087-45F8-B607-EC61E2092F81

P304

Q36734132-13EB520B-0DF3-4126-AC18-59D54C3F273E

P31

Q36734132-65854F90-55B9-48C8-823A-E9E436D2A655

P356

Q36734132-A2F2E82D-A542-4A0C-A67E-1835BD4BC4BF

P433

Q36734132-01959D51-22B0-4475-94F6-F00BDD3DBE4A

P478

Q36734132-F3BDE28F-703F-40E8-AF5C-532725B4AB15

P50

Q36734132-8E624B57-B4C0-4A6A-8235-DF6FD630FB51

P577

Q36734132-C81004E4-7EE8-498F-B804-BED2AA7B1A31

P698

Q36734132-44DF5D80-AB8D-479C-81EB-D42B4A6AE09D

P932

Q36734132-4CE6E244-6D02-4BDF-854D-DA783E3C4DAD

P356

P1433

CPT: pharmacometrics & systems pharmacology

P1476

Good Practices in Model-Inform ...... Application, and Documentation

@en

P2093

A Staab

http://www.w3.org/2001/XMLSchema#string

B Hamrén

http://www.w3.org/2001/XMLSchema#string

C Tornøe

http://www.w3.org/2001/XMLSchema#string

EFPIA MID3 Workgroup

http://www.w3.org/2001/XMLSchema#string

F Ivanow

http://www.w3.org/2001/XMLSchema#string

J L Steimer

http://www.w3.org/2001/XMLSchema#string

L Harnisch

http://www.w3.org/2001/XMLSchema#string

M Chenel

http://www.w3.org/2001/XMLSchema#string

N Frey

http://www.w3.org/2001/XMLSchema#string

O DellaPasqua

http://www.w3.org/2001/XMLSchema#string

P2860

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification

Modeling and simulation at the interface of nonclinical and early clinical drug development

Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development

Modelling and simulation in the pharmaceutical industry--some reflections.

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Modeling and simulation as a tool to bridge efficacy and safety data in special populations.

Ways to fit a PK model with some data below the quantification limit.

The Many Flavors of Model-Based Meta-Analysis: Part I-Introduction and Landmark Data.

Evaluation of different tests based on observations for external model evaluation of population analyses.

Clinical trial simulation in drug development.

P304

93-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12049

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27069774

http://www.w3.org/2001/XMLSchema#string

P932

4809625

http://www.w3.org/2001/XMLSchema#string